ModeX develops and uses proprietary platforms and digital technologies to develop the next generation of higher order multi-specific antibodies as novel therapies for cancer and infectious diseases, as well as nanoparticle technologies for the development of next generation vaccines.
At ModeX Therapeutics, our strategic focus is to develop highly flexible multi-specific antibody technology platforms with broad targeting and functional capabilities, providing significant differentiation from competing platforms. Building multi-specificity in a single product allows for synergistic targeting of antigens and receptors, as well as a streamlined manufacturing process for clinical development. In addition, the design of ModeX multi-specific antibodies is amenable to efficient gene-based delivery by mRNA or DNA vectors. Nanoparticle vaccine platforms provide controlled multivalent display of target antigens.
Drs. Elias Zerhouni and Gary Nabel created Breakthrough Laboratories within Sanofi Global R&D to explore long term, first-in-class breakthrough technologies and concepts.
Created Trispecific (CODV format) antibody that engages three targets with a single antibody, simplifying manufacturing and clinical development.
Science publication: A multi-specific Ab strategy to broaden the breadth, and potency against HIV-1 variants critical for treatment as well as prevention of HIV/AIDS. Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques (science.org)
Nature Cancer publication: A trispecific T cell engager (aCD38/aCD3xaCD28) incorporating a primary (anti-CD3) and a secondary (anti-CD28) T cell activation signals for enhanced efficacy in preclinical models. Trispecific antibodies enhance the therapeutic efficacy of tumor-directed T cells through T cell receptor co-stimulation | Nature Cancer
ModeX Therapeutics was founded by Gary Nabel, Elias Zerhouni, with R&D leaders, Zhi-yong Yang, Ronnie Wei, Chih-Jen Wei, and Elizabeth Nabel.
ModeX Therapeutics in-licensed first-generation tri-specific antibody technology, a tri-specific antibody to HIV currently in late phase I clinical testing, as well as an IND enabled EBV vaccine candidate.
ModeX Therapeutics developed its own proprietary, next generation multi-specific antibody technologies for Synergistic Targeting of Antigens and Receptors (STAR), and STEALTH delivery multispecifics technologies for tumor-specific activation.
Nature publication: Anti-tumor activity of a trispecific T cell engager aHer2/aCD3xaCD28 demonstrating the mechanistic role of CD4 T cells in mediating anti-tumor activity. A trispecific antibody targeting HER2 and T cells inhibits breast cancer growth via CD4 cells | Nature
Science Translational Medicine publication: A rationally designed vaccine targeting EBV viral surface glycoproteins prevents viral entry into host cells, and confers protection in animal model. A bivalent Epstein-Barr virus vaccine induces neutralizing antibodies that block infection and confer immunity in humanized mice (science.org)
ModeX Therapeutics became a wholly owned subsidiary of OPKO Health, a diverse healthcare company focused on improving patient lives.
Founded in October 2020 with headquarters in Natick, Mass., ModeX Therapeutics has developed highly flexible multi-specific antibody technology platforms with broad targeting and functional capabilities, simpler manufacturing and potentially better specificity and safety, providing significant differentiation from competing platforms. The design of these multi-specifics is amenable to gene-based delivery by mRNA or DNA vectors.
The ModeX product portfolio includes cancer immunotherapies that combine four specificities into one protein to improve targeting and immune killing, as well as masking or “stealth” technology to improve tumor-specific killing and reduce side effects.
For viral diseases, the lead targets of a broad and potent multi-specific antibody portfolio include HIV and SARS-CoV-2. A vaccine for Epstein-Barr virus is also in development.